The ACR20 and defining a threshold for response in rheumatic diseases: Too much of a good thing

Arthritis Research and Therapy

Volumn 16, Issue 1, 2014, Pages

  Felson, David T ^a   LaValley, Michael P ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; DISEASE ACTIVITY; NOTE; OUTCOME ASSESSMENT; RHEUMATIC DISEASE; SELF REPORT; STANDARDIZATION; TREATMENT RESPONSE; HUMAN; PROCEDURES; RHEUMATIC DISEASES; RHEUMATOLOGY; SEVERITY OF ILLNESS INDEX; STANDARDS; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENT;

ANTIRHEUMATIC AGENTS; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); RHEUMATIC DISEASES; RHEUMATOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84891536822     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4428     Document Type: Note

References (16)

1. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, Furst D, Goldsmith C, Kieszak S, Lightfoot R, Paulus H, Tugwell P, Weinblatt M, Widmark R, Williams HJ, Wolfe F. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993, 36:729-740. 10.1002/art.1780360601, 8507213.
2. Boers M, Tugwell P, Felson DT, van Riel PL, Kirwan JR, Edmonds JP, Smolen JS, Khaltaev N, Muirden KD. World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol Suppl 1994, 41:86-89.
3. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, Katz LM, Lightfoot R, Paulus H, Strand V, Tugwell P, Weinblatt M, Williams HJ, Wolfe F, Kieszak S. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995, 38:727-735. 10.1002/art.1780380602, 7779114.
4. van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996, 39:34-40. 10.1002/art.1780390105, 8546736.
5. van Gestel AM, Anderson JJ, van Riel PL, Boers M, Haagsma CJ, Rich B, Wells G, Lange ML, Felson DT. ACR and EULAR improvement criteria have compble validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology. J Rheumatol 1999, 26:705-711.
6. Weinblatt ME, Schiff M, Valente R, van der HD, Citera G, Zhao C, Maldonado M, Fleischmann R. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum 2013, 65:28-38. 10.1002/art.37711, 3572583, 23169319.
7. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Genovese MC, Wasko MC, Moreland LW, Weaver AL, Markenson J, Finck BK. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000, 343:1586-1593. 10.1056/NEJM200011303432201, 11096165.
8. Felson DT, Anderson JJ, Meenan RF. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials. Arthritis Rheum 1992, 35:1117-1125. 10.1002/art.1780351003, 1358078.
9. Nam JL, Winthrop KL, van Vollenhoven RF, Pavelka K, Valesini G, Hensor EM, Worthy G, Landewe R, Smolen JS, Emery P, Buch MH. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 2010, 69:976-986. 10.1136/ard.2009.126573, 20447957.
10. Launois R, Avouac B, Berenbaum F, Blin O, Bru I, Fautrel B, Joubert JM, Sibilia J, Combe B. Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian metaanalysis. J Rheumatol 2011, 38:835-845. 10.3899/jrheum.100665, 21239748.
11. Snapinn SM, Jiang Q. Responder analyses and the assessment of a clinically relevant treatment effect. Trials 2007, 8:31. 10.1186/1745-6215-8-31, 2164942, 17961249.
12. Uryniak T, Chan ISF, Fedorov VV, Jiang Q, Oppenheimer L, Snapinn SM, Teng C-H, Zhang J. Responder analyses - A PhRMA position paper. Stat Biopharmaceut Res 2011, 3:476-487.
13. Anderson JJ, Bolognese JA, Felson DT. Comparison of rheumatoid arthritis clinical trial outcome measures: a simulation study. Arthritis Rheum 2003, 48:3031-3038. 10.1002/art.11293, 14613263.
14. Altman DG, Royston P. The cost of dichotomising continuous variables. BMJ 2006, 332:1080. 1458573, 16675816.
15. van Vollenhoven RF, Felson D, Strand V, Weinblatt ME, Luijtens K, Keystone EC. American College of Rheumatology hybrid analysis of certolizumab pegol plus methotrexate in patients with active rheumatoid arthritis: data from a 52-week phase III trial. Arthritis Care Res (Hoboken) 2011, 63:128-134.
16. Kvien TK, Heiberg T, Hagen KB. Minimal clinically important improvement/difference (MCII/MCID) and patient acceptable symptom state (PASS): what do these concepts mean?. Ann Rheum Dis 2007, 66:iii40-iii41. 2095292, 17934093.